首页> 美国卫生研究院文献>Cancer Biology Medicine >Texosome-based drug delivery system for cancer therapy: from past to present
【2h】

Texosome-based drug delivery system for cancer therapy: from past to present

机译:基于Texosome的用于癌症治疗的药物输送系统:从过去到现在

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rising worldwide cancer incidence and resistance to current anti-cancer drugs necessitate the need for new pharmaceutical compounds and drug delivery system. Malfunction of the immune system, particularly in the tumor microenvironment, causes tumor growth and enhances tumor progression. Thus, cancer immunotherapy can be an appropriate approach to provoke the systemic immune system to combat tumor expansion. Texosomes, which are endogenous nanovesicles released by all tumor cells, contribute to cell-cell communication and modify the phenotypic features of recipient cells due to the texosomes’ ability to transport biological components. For this reason, texosome-based delivery system can be a valuable strategy for therapeutic purposes. To improve the pharmaceutical behavior of this system and to facilitate its use in medical applications, biotechnology approaches and mimetic techniques have been utilized. In this review, we present the development history of texosome-based delivery systems and discuss the advantages and disadvantages of each system.
机译:全球范围内癌症发病率的上升和对当前抗癌药物的耐药性使得需要新的药物化合物和药物递送系统。免疫系统的功能异常,特别是在肿瘤微环境中,会导致肿瘤生长并促进肿瘤进展。因此,癌症免疫疗法可以是激发全身免疫系统对抗肿瘤扩展的合适方法。 Texosomes是所有肿瘤细胞释放的内源性纳米囊泡,由于该Texosomes转运生物成分的能力,它们有助于细胞之间的通信并改变受体细胞的表型特征。因此,基于线粒体的递送系统可能是用于治疗目的的有价值的策略。为了改善该系统的药学行为并促进其在医学应用中的使用,已经利用了生物技术方法和模拟技术。在这篇综述中,我们介绍了基于体的递送系统的发展历史,并讨论了每种系统的优缺点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号